Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Lurbinectedin in Combination with Paclitaxel and Bevacizumab for the Treatment of Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancers

Trial Status: active

This phase I trial tests the best dose of the combination of lurbinectedin, paclitaxel, and bevacizumab in treating patients with ovarian cancer that has not responded to previous platinum therapy (platinum-refractory) or that has come back after treatment with platinum-therapy (platinum-resistant). Lurbinectedin is a drug that can bind to deoxyribonucleic acid (DNA), causing delays in DNA replication and repair and inducing cell death. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving lurbinectedin in combination with paclitaxel and bevacizumab may be more effective at treating patients with platinum-refractory or platinum-resistant ovarian cancer.